Catalyst
Slingshot members are tracking this event:
AbbVie 's (ABBV) Phase 3 Trial Evaluating Veliparib (ABT-888) in Treatment of Patients with Ovarian Cancer Expected to Conclude in January 2019
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABBV |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 10, 2019
Occurred Source:
https://www.ascopost.com/issues/november-10-2019/veliparib-plus-chemotherapy-meets-primary-endpoint-in-advanced-ovarian-cancer/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Veliparib, Ovarian Cancer
